NEW YORK, Sept. 13, 2016 -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Goldcorp Inc. (“Goldcorp” or the “Company”) (NYSE:GG) of the October 24, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased Goldcorp stock or options between March 31, 2014 and August 24, 2016 (the “Class Period”). The case, Robert Cowan v. Goldcorp, Inc. et al, No. 2:16-cv-06391 was filed on August 25, 2016, and has been assigned to Judge Fernando M. Olguin.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose the severity of selenium levels in groundwater around its Peñasquito Mine in Mexico.
Specifically, on August 24, 2016, Reuters reported that Mexican regulators were examining whether Goldcorp broke reporting or disclosure regulations in its handling of a long-running leak of contaminated water at the Peñasquito Mine that had been occurring as early as October 2013.
After the announcement, Goldcorp’s share price fell from $17.69 per share on August 23, 2016 to a closing price of $16.05 on August 24, 2016 —a $1.64 or a 9.27% drop.
Request more information now by clicking here: www.faruqilaw.com/GG. There is no cost or obligation to you.
Take Action
If you invested in Goldcorp stock or options between March 31, 2014 and August 24, 2016 and would like to discuss your legal rights, visit www.faruqilaw.com/GG. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding Goldcorp’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 Attn: Richard Gonnello, Esq. [email protected] Telephone: (877) 247-4292 or (212) 983-9330


Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
First Western Ship Transits Strait of Hormuz Since Iran War Began
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Apple Turns 50: From Garage Startup to AI Crossroads
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 



